New Direction for Key Capital
November 10, 2021
New leadership for Key Capital following the sad passing of founder, Chairman and CEO, Peter Boonen.
New leadership for Key Capital following the sad passing of founder, Chairman and CEO, Peter Boonen.
NEW YORK, NY, April 29, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises it is evident the COVID situation in India is a humanitarian catastrophe, and that although the head of WHO states it is “beyond heartbreaking”, it appears that the COVID crisis in India will unfortunately get a lot worse.
NEW YORK, NY, April 26, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that Immunitor, its Licensing partner, continues to receive favorable reports from people in Asian and African countries using the Immunitor HAP-V+ Immune Supplement in cases of respiratory infections.
NEW YORK, NY, April 8, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that in association with its partner, global oral pill vaccine pioneer Immunitor (Thailand) Co., Ltd, the Company is today launching its unique M.vaccae and magnesium dietary supplement in the $18 billion Anxiety and Stress market.
NEW YORK, NY, April 7, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises the Company is launching https://MaxCellLife.com today specializing in the sales and marketing of science driven supplement and skincare products.
NEW YORK, NY, March 12, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that in association with its partner, global oral pill vaccine pioneer Immunitor, it will be launch a unique M.vaccae and Magnesium dietary supplement in the $18 billion Anxiety and Stress market.
NEW YORK, NY, March 3, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) in response to recent global media coverage of a scramble or race to develop oral pill vaccines for disease treatment and/or for application to viruses including SARS-CoV-2, advises that, Immunitor, its Licensor and Partner is well recognized globally as a pioneer in oral vaccines development.
NEW YORK, NY, February 18, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that it continues to work with Immunitor, its partner and Licensor, to progress further research and development of its breakthrough therapeutic vaccines, and for several unique supplements.